| Primary |
| Renal Transplant |
33.3% |
| Immunosuppression |
21.5% |
| Prophylaxis Against Transplant Rejection |
6.7% |
| Polymyositis |
6.2% |
| Graft Versus Host Disease |
4.1% |
| Bone Marrow Conditioning Regimen |
3.1% |
| Product Used For Unknown Indication |
3.1% |
| Prophylaxis |
3.1% |
| Renal Vasculitis |
3.1% |
| Drug Exposure During Pregnancy |
2.6% |
| Liver Transplant |
2.6% |
| Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis |
1.5% |
| Autoimmune Lymphoproliferative Syndrome |
1.5% |
| Chronic Lymphocytic Leukaemia |
1.5% |
| Crohn's Disease |
1.0% |
| Focal Segmental Glomerulosclerosis |
1.0% |
| Glomerulonephritis Membranoproliferative |
1.0% |
| Heart Transplant |
1.0% |
| Lupus Nephritis |
1.0% |
| Vasculitis |
1.0% |
|
| Bronchiectasis |
16.3% |
| Death |
8.2% |
| Hypogammaglobulinaemia |
8.2% |
| Abortion Spontaneous |
6.1% |
| Apoptosis |
6.1% |
| Benign Intracranial Hypertension |
6.1% |
| Cardiac Arrest |
6.1% |
| Chest Pain |
6.1% |
| Blood Creatinine Increased |
4.1% |
| Idiopathic Pneumonia Syndrome |
4.1% |
| Pancytopenia |
4.1% |
| Progressive Multifocal Leukoencephalopathy |
4.1% |
| Protein Urine Present |
4.1% |
| Renal Failure Acute |
4.1% |
| Abortion Induced |
2.0% |
| Angina Unstable |
2.0% |
| Arthralgia |
2.0% |
| Aspartate Aminotransferase Increased |
2.0% |
| Bacteraemia |
2.0% |
| Basedow's Disease |
2.0% |
|
| Secondary |
| Prophylaxis Against Transplant Rejection |
27.2% |
| Renal Transplant |
26.2% |
| Immunosuppression |
14.7% |
| Product Used For Unknown Indication |
7.0% |
| Immunosuppressant Drug Therapy |
3.4% |
| Liver Transplant |
2.4% |
| Renal Vasculitis |
1.8% |
| Prophylaxis |
1.7% |
| Graft Versus Host Disease |
1.6% |
| Acute Myeloid Leukaemia |
1.5% |
| Bone Marrow Conditioning Regimen |
1.5% |
| Lymphoma |
1.5% |
| Prophylaxis Against Graft Versus Host Disease |
1.5% |
| Systemic Lupus Erythematosus |
1.3% |
| Polymyositis |
1.3% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
1.2% |
| Heart Transplant |
1.2% |
| Stem Cell Transplant |
1.2% |
| Gastrointestinal Disorder |
1.0% |
| Upper Respiratory Tract Inflammation |
1.0% |
|
| Bronchiectasis |
13.6% |
| Hypogammaglobulinaemia |
12.3% |
| Blood Cortisol Decreased |
9.9% |
| Blood Immunoglobulin G Decreased |
9.9% |
| Diarrhoea |
8.0% |
| Granulocytopenia |
6.8% |
| Nasopharyngitis |
6.2% |
| Idiopathic Pneumonia Syndrome |
4.3% |
| Immune Reconstitution Syndrome |
3.7% |
| Pyrexia |
3.7% |
| Arthralgia |
3.1% |
| Basedow's Disease |
3.1% |
| Progressive Multifocal Leukoencephalopathy |
2.5% |
| Blood Creatinine Increased |
1.9% |
| Cardiac Arrest |
1.9% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
1.9% |
| Graft Versus Host Disease |
1.9% |
| Haemoglobin Decreased |
1.9% |
| Infarction |
1.9% |
| Multi-organ Failure |
1.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.9% |
| Prophylaxis Against Graft Versus Host Disease |
10.1% |
| Prophylaxis |
8.2% |
| Stem Cell Transplant |
5.3% |
| Bone Marrow Conditioning Regimen |
5.3% |
| Renal Transplant |
4.9% |
| Immunosuppressant Drug Therapy |
3.5% |
| Hypertension |
3.3% |
| Myelodysplastic Syndrome |
3.3% |
| Infection Prophylaxis |
2.9% |
| Premedication |
2.9% |
| Immunosuppression |
2.8% |
| Prophylaxis Against Transplant Rejection |
2.7% |
| Nausea |
2.3% |
| Liver Transplant |
2.2% |
| Graft Versus Host Disease |
2.2% |
| Prophylaxis Of Nausea And Vomiting |
2.2% |
| Antifungal Prophylaxis |
1.5% |
| Depression |
1.2% |
| Acute Myeloid Leukaemia |
1.1% |
|
| Acute Graft Versus Host Disease |
21.1% |
| Death |
6.6% |
| Pneumonia |
6.6% |
| Complications Of Transplanted Kidney |
5.3% |
| Cystitis Haemorrhagic |
5.3% |
| Graft Loss |
5.3% |
| Haematological Malignancy |
5.3% |
| Sepsis |
5.3% |
| Thrombotic Microangiopathy |
5.3% |
| Chronic Graft Versus Host Disease |
3.9% |
| Disease Recurrence |
3.9% |
| Fluid Overload |
3.9% |
| Renal Impairment |
3.9% |
| Acute Myocardial Infarction |
2.6% |
| Bk Virus Infection |
2.6% |
| Blood Creatinine Increased |
2.6% |
| Cytomegalovirus Infection |
2.6% |
| Erythema Infectiosum |
2.6% |
| Febrile Neutropenia |
2.6% |
| Glomerulonephropathy |
2.6% |
|
| Interacting |
| Hiv Infection |
37.5% |
| Immunosuppression |
37.5% |
| Dyslipidaemia |
12.5% |
| Renal Impairment |
12.5% |
|
| Drug Interaction |
50.0% |
| Rhabdomyolysis |
50.0% |
|
